This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Winners & Losers: Indevus

Pharma stocks mostly fell while their biotech counterparts generally kept in the green midweek, presenting a mixed platter of regulatory and business updates Wednesday.

Indevus (IDEV) shares slid 69% to $1.26 Wednesday on news of a Food and Drug Administration delay. The company said regulators will not approve Nebido, a long-acting injectable testosterone, without additional safety data and a new clinical trial expected to take 18 months.

The FDA also said Wednesday that it's looking into a possible cancer risk in a class of drugs called tumor necrosis factor blockers (TNF inhibitors) in young arthritis patients. The drugs include Abbott's (ABT) Humira, Schering-Plough's (SGP) Remicade and Amgen (AMGN) and Wyeth's (WYE) Enbrel.

The agency issued an "early communication" that it has received 30 reports of cancer development in children and young adults who were taking the drugs over the last 10 years. About half were lymphomas, or immune system cancer.

Amgen and Wyeth, which issued a statement in response, traded up 0.8% and down 0.9%, respectively. Abbott's shares were down 0.5%, and Schering fell 0.4%.

In ratings actions, Cowen and Co. analyst Steve Scala upgraded Eli Lilly (LLY - Get Report) to outperform from neutral on Wednesday, on optimism regarding the upcoming FDA decision on Lilly's blood-thinner Effient. Lilly's shares added 1.5% to $49.04.

Scala also upgraded Novartis (NVS - Get Report) to outperform from neutral, but downgraded Bristol-Myers Squibb (BMY - Get Report) to neutral from outperform. Those pharma stocks each traded down 1.4%.

The Amex pharmaceutical index, which includes Lilly and Bristol but not Novartis, was down 0.6% at 296.86. Biotechnology companies seemed to fare better. The Nasdaq and Amex biotech indices both added 0.9%.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BMY $71.96 0.00%
LLY $76.75 0.00%
NVS $76.84 0.00%
SQNM $1.28 0.00%
AAPL $93.98 0.36%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs